LifeArc

Key takeaways

LifeArc belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect LifeArc to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of LifeArc from memory before moving on to harder problems.

Reference excerpt

LifeArc is a British self-funded medical research organisation, with a focus on rare diseases and drug-resistant infections or antimicrobial resistance. It is both a limited company by guarantee and a registered charity. The organisation is known for its expertise in research translation and bring medical innovations closer to patient impact. This includes humanising the antibody that would become the immunotherapy cancer drug, Keytruda (pembrolizumab), as well as 4 other licensed medicines. In 2019, the sale of a portion of royalties in Keytruda helped to build a strategic investment portfolio and gave LifeArc financial independence. LifeArc's income derives from several sources, including royalties, commercialisation of scientific platforms, a ventures portfolio and investment portfolio.

History The organisation’s work began in 1984 as a single-site science park with a focus on antibody development. In 1999 it became the commercialisation division of the Medical Research Council (MRC), Medical Research Council Technology (MCR-T). As MRC-T, the organisation helped to translate research funded by the MRC and other life sciences organisations, with a combination of scientific expertise and commercial advice. The organisation officially rebranded as LifeArc in 2017. Throughout its history, LifeArc has used its expertise in translational research to help translate scientific discoveries into innovations for patients. This includes licensed medicines, Keytruda (pembrolizumab) (Merck/MSD): immunotherapy for various cancers, Leqembi (lecanemab) (Easai / BioArctic): for Alzheimer’s disease, Actemra (tocilizumab) (Hoffmann-La Roche/Chugai): for rheumatoid arthritis and other conditions, Tysabri (natalizumab) (Biogen Idec/Elan): for multiple sclerosis and Entyvio (vedolizumab) (Millenium Pharma/Takeda): for ulcerative colitis and Crohn's disease. Keytruda is one of the best selling drugs in history, generating $31.7 billion in sales in 2025. In May 2019, LifeArc announced it had sold part of its royalty rights for Keytruda to a subsidiary of Canada Pension Plan Investment Board (CPPIB) for US$1.297 billion (approximately £1 billion). This capital helped to build a strategic investment portfolio, returns from which are reinvested to ensure continued support of high impact science and cement LifeArc’s status as ‘self-funded’. In 2021, LifeArc launched a new research strategy, “Making life science life changing”, to translate basic science into new ideas and opportunities for patients. Across 2025, LifeArc refined its strategy to focus on rare diseases and drug-resistant infections. It also expanded its portfolio to include clinical research.

Operations

Management LifeArc is led by chief executive officer (CEO) Dr Sam Barrell, CBE and a board of trustees. The board is chaired by Dr Ian Gilham and includes Lynne Robb (vice chair), Dr Sam Barrell (CEO), Stéphane Maikovsky (deputy CEO and chief financial officer), Dr Terri Cooper, Dr Sameer Mistry, Daniel Morgan, Ian Nicholson, Jo Pisani, Susan Wallcraft and David Zahn. Barrell became CEO in October 2024. Melanie Lee served as CEO between 2018 and 2023. Stéphane Maikovsky served as interim CEO after Lee’s departure and before Barrell’s appointment.

Research and funding Much of LifeArc’s research is focused on healthcare areas where patient needs are urgent and progress is slow, but the science ready for translation. Within rare disease, this includes childhood cancer, chronic and rare respiratory diseases, motor neuron disease and rare dementias. It also has a focus on drug-resistant infections within the context of global health. LifeArc’s research funding spans multiple funding schemes, to recipients across the UK and globally, often as part of co-funding agreements. Its funding model is one of “value add”, combining financial support with strategic partnership and input from in-house experts, including in drug discovery and development, clinical trial support, data science and commercialisation. The LifeArc Translational Centres for Rare Disease are a £40 million investment to establish 4 specialised research hubs to accelerate the development of new tests, treatments and potentially cures for people living with rare medical conditions. It's Primer Fund supports the development of tools and tests that could be used in the primary care setting to accelerate diagnosis for people with motor neuron disease (MND). Its Rare Disease Clinical Trials Programme funds clinical programmes to accelerate the development of drugs, devices and diagnostics for people with rare disease. LifeArc co-founded PACE (Pathways to Antimicrobial Clinical Efficiency) in partnership with Innovate UK and Medicines Discovery Catapult, providing funding and wraparound support for projects tackling drug-resistant bacterial infections. Over the last three decades, the organisation has built scientific platforms and capabilities to support partners to advance their research. This research includes antibody humanisation, which helps partners to humanise monoclonal antibodies from a wide range of species. This platform has led to 5 approved therapies, including Keytruda (pembrolizumab). It also works in antibody discovery, using its proprietary B-SMArT™ platform and clinically validated transgenic Kymouse platform to generate fully human therapeutic antibodies. LifeArc platforms also include clinical trial support, data science, induced pluripotent stem cell technology and microbiology, as well as expertise in intellectual property identification, protection and commercialisation and technology transfer. With these capabilities, the organisation supports its partners to progress their research through the translational pipeline.

… excerpt ends here. Continue reading the full article.

Worked examples

Example 1 — a first encounter with LifeArc

Start with the simplest possible case. Write down what LifeArc claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to LifeArc before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about LifeArc ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of LifeArc

In research: LifeArc appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses LifeArc in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: LifeArc is common in secondary-school and first-year university syllabi. It links to neighbouring topics Charities based in London, Companies based in the London Borough of Camden, Medical research institutes in the United Kingdom, so understanding it makes those chapters shorter.
In everyday life: Look for LifeArc outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

How to study LifeArc in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what LifeArc means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain LifeArc out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is LifeArc in simple terms?

LifeArc is a British self-funded medical research organisation, with a focus on rare diseases and drug-resistant infections or antimicrobial resistance. It is both a limited company by guarantee and a registered charity.

Why does LifeArc matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study LifeArc?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on LifeArc.